PD-1单抗Pembrolizumab联合靶动脉栓塞化疗治疗中晚期非小细胞肺癌的疗效及对患者血清hCAP18、Pokemon水平及KPS评分的影响  

Efficacy of PD-1 Monoclonal Antibody Pembrolizumab Combined with Target Arterial Embolization Chemotherapy in the Treatment of Patients with Advanced NSCLC and Its Effect on Serum hCAP18,Pokemon Levels and KPS Score

作　　者：张华 高亚娜 韩革燕 ZHANG Hua;GAO Yana;HAN Geyan(The Affiliated Cancer Hospital of Zhengzhou University(Henan Provincial Cancer Hospital),Zhengzhou,450000)

机构地区：[1]郑州大学附属肿瘤医院,河南省肿瘤医院,450000

出　　处：《实用癌症杂志》2022年第12期2008-2011,2015,共5页The Practical Journal of Cancer

摘　　要：目的探讨程序性死亡受体-1(PD-1)单抗Pembrolizumab联合靶动脉栓塞化疗治疗中晚期非小细胞肺癌的疗效及对患者血清抗菌肽人类阳离子抗菌蛋白18(hCAP18)、POK红系髓性致癌因子(POK)水平及生存质量(KPS)的影响。方法将108例处于中晚期非小细胞肺癌患者随机分为观察组54例与对照组54例,观察组患者给予PD-1单抗Pembrolizumab联合靶动脉栓塞化疗治疗,对照组患者仅给予靶动脉栓塞化疗治疗。比较2组患者治疗后疗效,治疗前后血清hCAP18、Pokemon水平变化、KPS评分变化及不良反应发生情况。结果观察组患者临床疗效总有效率(87.04%)显著高于对照组(70.37%)(P<0.05)。治疗后观察组血清hCAP18、Pokemon水平分别为(766.45±243.18)μg/L、(84.82±21.78)ng/mL,显著低于对照组血清hCAP18(1211.27±469.34)μg/L、Pokemon(109.54±28.66)ng/mL(P<0.05)。治疗后观察组生存质量总改善率(96.30%)显著高于对照组(83.33%)(P<0.05)。治疗后2组患者皮疹、白细胞减少、肝功能损伤等不良反应情况比较无明显差异(P>0.05)。结论PD-1单抗Pembrolizumab联合靶动脉栓塞化疗治疗具有协同作用,可以提高疗效,有效改善患者血清hCAP18、Pokemon水平与KPS评分,且未增加不良反应发生,安全性较高。Objective To investigate the efficacy of programmed death-1(PD-1)monoclonal antibody pembrolizumab combined with target arterial chemoembolization(TACE)in the treatment of patients with advanced non-small cell lung cancer(NSCLC)and its effect on serum antimicrobial peptide human cationic antimicrobial protein 18(hCAP18),POK erythroid myelogenic factor(POK)levels and quality of life(KPS)in patients.Methods One hundred and eight patients with advanced non-small cell lung cancer were selected and randomly divided into the observation group(n=54)and the control group(n=54).Patients in the observation group were treated with PD-1 monoclonal antibody Pembrolizumab combined with target artery embolization chemotherapy,while those in the control group were treated with target artery embolization chemotherapy only.The efficacy after treatment,changes in serum hCAP18 and Pokemon levels before and after treatment,changes in KPS scores and occurrence of adverse reactions were compared between the two groups.Results After treatment,there were 25 cases of CR and 22 cases of PR in the observation group,18 cases of complete remission(CR)and 20 cases of partial remission(PR)in the control group.The overall response rate(ORR)of 87.04%in the observation group was significantly higher than that of 70.37%in the control group(P<0.05).After treatment,the serum hCAP18 and Pokemon levels in the observation group were(766.45±243.18)μg×L^(-1) and(84.82±21.78)ng×mL^(-1),respectively,which were significantly lower than(1211.27±469.34)μg×L^(-1)(109.54±28.66)ng×mL^(-1) in the control group(P<0.05).Conclusions PD-1 monoclonal antibody Pembrolizumab combined with target artery embolization chemotherapy has a synergistic effect and can improve the efficacy,effectively improve the serum hCAP18,Pokemon levels and KPS score of patients,without increasing the occurrence of adverse reactions but high safety.

关 键 词：程序性死亡受体-1 帕博利珠单抗 靶动脉栓塞化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]